Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Sareum Holdings investors receive update on progress of cancer drug

SRA737 is a checkpoint kinase-1 inhibitor, one of a new breed of treatments
Sareum Holdings investors receive update on progress of cancer drug
The clinical trials appear to be progressing well

Investors in Sareum Holdings PLC (LON:SAR) received an update on the company’s most advanced drugs candidate via Sierra Oncology (NASDAQ:SRRA), the NASDAQ-listed group with which Sareum has a licensing deal.

SRA737 is a checkpoint kinase-1 (Chk1) inhibitor, one of a new breed of cancer treatments, and is currently Phase I/II trials targeting various strains of the killer disease.

READ: Sareum Holdings pleased as Sierra Oncology advances cancer drug trial

It is being tested as a single therapy, in combination with a low-dose chemotherapy called gemcitabine, and in harness with a PARP inhibitor, which helps cells repair themselves.

Sierra in its update said it further refined its single therapy study to focus on high-grade serous ovarian cancer (HGSOC), “supported by emerging data in the field that provides clinical validation for Chk1 inhibition in this indication”.

Priority to ovarian cancer patients 

“Accordingly, we are prioritising the enrolment of approximately 65 genetically defined HGSOC patients into this trial, while continuing to enrol patients into the trial's other indications, although with lower priority," added Dr Nick Glover, Sierra’s chief executive.

"However, given that this amendment will require time to operationalise, we anticipate preliminary data from our monotherapy trial will be reported in the first half of 2019."

The American company is also planning to give priority to ovarian cancer patients as it recruits for its trial deploying SRA737 alongside the low-dose chemo.

In the Phase II expansion portion of the trial, which is recruiting 80 patients, 20 will be HGSOC sufferers, replacing an originally-proposed cohort of urothelial cancer patients.

Preliminary data from this trial is now expected in the first half of 2019.

Derren Nathan, of small-cap broker Hybridan, said: "We believe that the change in the trial designs to prioritise patients with high grade serous ovarian cancer (HGSOC) optimises the chance of a positive outcome, given the validation of this target evidenced by Lily’s Prexasertib data released earlier this year.

"Pre-clinical data by Sierra is also supportive of this rationale. We therefore believe the trade-off between trial optimisation and slightly extended timeline, is a decision well made."

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use